Status: In progress

KPH Healthcare Services Inc. a/k/a Kinney Drugs Inc., et al. v. Mylan N.V., et al., Case No. 2:20-cv-02065-DDC-TJJ

  • Deadline to file a claim: 05/29/2025
  • Proof of Purchase Required: Yes
  • Potential Individual Reward: TBD
  • Total Settlement Amount: $73.5 million
  • Nationwide

Status: In progress

KPH Healthcare Services Inc. a/k/a Kinney Drugs Inc., et al. v. Mylan N.V., et al., Case No. 2:20-cv-02065-DDC-TJJ

  • Deadline to file a claim: 05/29/2025
  • Proof of Purchase Required: Yes
  • Potential Individual Reward: TBD
  • Total Settlement Amount: $73.5 million
  • Nationwide

Status: In progress

KPH Healthcare Services Inc. a/k/a Kinney Drugs Inc., et al. v. Mylan N.V., et al., Case No. 2:20-cv-02065-DDC-TJJ

  • Deadline to file a claim: 05/29/2025
  • Proof of Purchase Required: Yes
  • Potential Individual Reward: TBD
  • Total Settlement Amount: $73.5 million
  • Nationwide

Status: In progress

KPH Healthcare Services Inc. a/k/a Kinney Drugs Inc., et al. v. Mylan N.V., et al., Case No. 2:20-cv-02065-DDC-TJJ

The Mylan Pharmaceuticals settlement benefits entities that purchased EpiPen or generic EpiPen products directly from Mylan or Teva between March 13, 2014, and Feb. 6, 2025.

  • Deadline to file a claim: 05/29/2025
  • Proof of Purchase Required: Yes
  • Potential Individual Reward: TBD
  • Total Settlement Amount: $73.5 million
  • Nationwide

Edited by: Top Class Actions  |  March 17, 2025

Category: Closed Class Actions

This settlement is closed!

Please see what other class action settlements you might qualify to claim cash from in our Open Settlements directory!

Exterior of Mylan drug manufacturing plant
(Photo Credit: Steve Heap/Shutterstock)

Mylan has agreed to a $73.5 million settlement to resolve claims that it illegally conspired with Pfizer and other pharmaceutical companies to suppress generic EpiPens in order to extend its monopoly.

The Mylan Pharmaceuticals settlement benefits entities that purchased EpiPen or generic EpiPen products directly from Mylan or Teva between March 13, 2014, and Feb. 6, 2025.

According to plaintiffs in the EpiPen monopoly class action lawsuit, Mylan conspired with Pfizer and Teva to suppress the release of generic EpiPen products. This scheme allegedly allowed the pharmaceutical companies to extend their monopolies and charge higher prices.

Mylan Pharmaceuticals is a global generic and specialty pharmaceutical company which merged with Upjohn, a Pfizer division, in 2020 to form Viatris.

Mylan hasn’t admitted any wrongdoing but agreed to the $73.5 million settlement to resolve the EpiPen monopoly class action lawsuit.

Under the terms of the Mylan Pharmaceuticals settlement, entities can receive a payment based on the number of branded or generic EpiPen products they purchased during the class period. No payment estimates are available at this time.

Claimants must include valid documentation to support their claims.

The deadline for exclusion and objection is May 29, 2025.

The final approval hearing for the settlement is scheduled for May 29, 2025.

Class members must submit a valid claim form by May 29, 2025.

Who’s Eligible

Entities that purchased EpiPen or generic EpiPen products directly from Mylan or Teva between March 13, 2014, and Feb. 6, 2025.

Potential Award

TBD

Proof of Purchase

Invoices, order confirmation, receipts, work orders and other proof of purchase.

Claim Form

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

05/29/2025

Case Name

KPH Healthcare Services Inc. a/k/a Kinney Drugs Inc., et al. v. Mylan N.V., et al., Case No. 2:20-cv-02065-DDC-TJJ, in the U.S. District Court for the District of Kansas.

Final Hearing

05/29/2025

Settlement Website
Claims Administrator

EpiPen Direct Purchaser
c/o A.B. Data, Ltd.
P.O. Box 173113
Milwaukee, WI 53217
[email protected]
866-778-6568

Class Counsel

Linda P. Nussbaum
NUSSBAUM LAW GROUP PC

Michael L. Roberts
ROBERTS LAW FIRM US PC

Defense Counsel

Adam K. Levin
David M. Foster
Carolyn A. DeLone
Michael D. Gendall
HOGAN LOVELLS US LLP

Brian C. Fries
James Moloney
LATHROP GPM LLP

Read About More Class Action Lawsuits & Class Action Settlements:

We tell you about cash you can claim EVERY WEEK! Sign up for our free newsletter.

14 thoughts on$73.5M Mylan Pharmaceuticals EpiPen monopoly class action settlement

  1. Debbie Chambers says:

    Please add me

  2. Andra Kuzilik says:

    add my son and myself

  3. Brandy cole says:

    Add me please

  4. Barbara Rogers says:

    Please add me

  5. PRAKASH C SHAH says:

    Add me

  6. Delight Phillips says:

    I’ve been using Epipens and generics for it now for at least 20 years and gotten dozens, but who the heck keeps RECEIPTS?? You should be able to show a statement from your pharmacy or doctor that you’ve used them. My pharmacy’s records only go back ONE YEAR. That’s Walgreen’s and I’m sure a lot of other people’s pharmacies are the same. This is a crock!

    1. Tina says:

      I agree. I just took my epi pen out of my pouch that I carry it in everyday and it reads in clear “Mylan”. This is how they get away with not paying. They’re really aware that people won’t have these receipts or documentation they’re requesting. This pisses me off so bad.

  7. askmrlee says:

    Unless you bought these in bulk FOR RESALE from Mylan or Teva you DO NOT QUALIFY for this particular settlement. Why this is even posted here is questionable. Filling your prescription from Walgreens, CVS, Walmart, Kroger, your neighborhood pharmacy, etc means you are not a direct buyer and are not included in this settlement.

    1. Stephanie Porcaro says:

      What about the three ingredients in the mylan pharm co meds that aren’t approved by the fda, where’s that class action? Almost had my gall bladder removed from it and filed a complaint.

    2. Stephanie Porcaro says:

      What about the three ingredients in the mylan pharm co meds that aren’t approved by the fda, where’s that class action? Almost had my gall bladder removed from it and filed a complaint.

    3. Mrs. T says:

      Thank you for clearing this up. I was thinking the same. I was going to submit a claim but I realized I didn’t purchase directly from the company.

  8. Dean says:

    Proof of purchase required? From 2014? Pffft!

  9. Alisa Patterson says:

    He signed me up for this class action lawsuit because I have bought plenty of these back in 2014 and 15 and 16 17 now I don’t have the receipts from them because I stopped getting them from those people and started buying them from the stores around my house and now I see why my breathing is not so great either

    1. Cassie says:

      This is only for direct buyers like CVS, Walmart, Kroger, etc. it doesn’t include us

Leave a Reply

Your email address will not be published. By submitting your comment and contact information, you agree to receive marketing emails from Top Class Actions regarding this and/or similar lawsuits or settlements, and/or to be contacted by an attorney or law firm to discuss the details of your potential case at no charge to you if you qualify. Required fields are marked *

Please note: Top Class Actions is not a settlement administrator or law firm. Top Class Actions is a legal news source that reports on class action lawsuits, class action settlements, drug injury lawsuits and product liability lawsuits. Top Class Actions does not process claims and we cannot advise you on the status of any class action settlement claim. You must contact the settlement administrator or your attorney for any updates regarding your claim status, claim form or questions about when payments are expected to be mailed out.